Description Background
ChemicalBook > CAS DataBase List > Lanreotide

Lanreotide

Description Background
Product Name
Lanreotide
CAS No.
108736-35-2
Chemical Name
Lanreotide
Synonyms
IPSTYL;AUTOGEL;DC-13-116;BIM-23014;LANREOTIDE;bim-23014c;Somatuline;ANGIOPEPTIN;LaroMustine;D8-Lanreotide
CBNumber
CB6190280
Molecular Formula
C54H69N11O10S2
Formula Weight
1096.32
MOL File
108736-35-2.mol
More
Less

Lanreotide Property

Boiling point:
1508.2±65.0 °C(Predicted)
Density 
1.40±0.1 g/cm3(Predicted)
storage temp. 
Keep in dark place,Sealed in dry,Store in freezer, under -20°C
pka
9.90±0.15(Predicted)
Sequence
D-2-Nal-[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2
InChIKey
PUDHBTGHUJUUFI-VHAAONQQNA-N
More
Less

Safety

WGK Germany 
3
HS Code 
3504009000
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H361Suspected of damaging fertility or the unborn child

Precautionary statements

P201Obtain special instructions before use.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P308+P313IF exposed or concerned: Get medical advice/attention.

More
Less

N-Bromosuccinimide Price

Usbiological
Product number
L1275
Product name
Lanreotide
Packaging
200ug
Price
$297
Updated
2021/12/16
Chemenu
Product number
CM100725
Product name
Lanreotide acetate
Purity
97%
Packaging
1g
Price
$729
Updated
2021/12/16
Crysdot
Product number
CD22005163
Product name
Lanreotide
Purity
97%
Packaging
1mg
Price
$50
Updated
2021/12/16
Crysdot
Product number
CD22005163
Product name
Lanreotide
Purity
97%
Packaging
5mg
Price
$105
Updated
2021/12/16
More
Less

Lanreotide Chemical Properties,Usage,Production

Description

Lanreotide is a synthetic octapeptide analogue of somatostatin with enhanced metabolic stability compared with somatostatin. It binds with high affinity to and stimulates the somatostatin receptors SSTR2 and SSTR5, with relatively greater potency at SSTR2 and very low binding to SSTR1, SSTR3 and SSTR4. It is used to treat acromegaly and neuroendocrine tumors.

Chemical Properties

White to off-white lyophilised powder

Uses

Antineoplas tic.

Side effects

Lanreotide depot was generally well tolerated, as 88% of patients had adverse events, compared with the placebo at 90%. Most adverse events were mild (17%) or moderate (44%) in both lanreotide and placebo groups. The most common adverse event was diarrhea at 26% in the lanreotide group and 9% with placebo. Abdominal pain was recorded in 14% of patients taking lanreotide but only occurred in 2% of patients taking placebo. Cholelithiasis occurred in 10% of patients but only 3% in the placebo group. Hyperglycemia occurred in 5% of lanreotide patients but was not observed in placebo patients.

in vivo

Lanreotide (2.5-10mg/kg; s.c.; daily for 5 days) results in tumor growth inhibition[1].

Animal Model:Male nude mice, 8 weeks old and 20–25?g in body weight (GH3 tumor-bearing nude mice)[1]
Dosage:2.5, 5, 10?mg/kg
Administration:Subcutaneous; daily for 5 days
Result:Produced tumor growth inhibition.

Description

Lanreotide is an octapeptide, an analogue of a naturally occurring hormone, somatostatin.

Background

Lanreotide is a peptide inhibitor of a number of endocrine, neuroendocrine, exocrine and paracrine functions. It shows good affinity for peripheral somatostatin receptors (anterior pituitary and pancreatic). In contrast, its affinity for central receptors is much lower. This profile confers a good specificity of action at the level of growth hormone and digestive hormone secretion. Lanreotide shows a much longer duration of action than natural somatostatin. In addition, its marked selectivity for the secretion of growth hormone, compared to that of insulin, makes it a suitable candidate for the treatment of acromegaly. By inhibiting the synthesis of thyroid stimulating hormone (TSH), lanreotide also normalised thyroid function of patients with thyrotrophin secreting adenomas in 50% (8/16) of the per-protocol population treated for 6 months. There was no significant reduction in the size of the adenoma. Furthermore, the inhibitory action of lanreotide on intestinal exocrine secretion, d

Lanreotide Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Lanreotide Suppliers

China 224 Germany 1 India 5 Japan 1 Switzerland 1 United Kingdom 2 United States 13 Global 247
Adachibio Inc.
Tel
+81-8027837258; +8108027837258
Fax
0081-80278372055
Email
sales@adachibio.com
Country
Japan
ProdList
992
Advantage
58
More
Less

View Lastest Price from Lanreotide manufacturers

WUHAN FORTUNA CHEMICAL CO., LTD
Product
Lanreotide 108736-35-2
Price
US $0.00/g
Min. Order
1g
Purity
98%min
Supply Ability
1000g
Release date
2023-01-12
Henan Aochuang Chemical Co.,Ltd.
Product
Lanreotide 108736-35-2
Price
US $0.00-0.00/kg
Min. Order
1kg
Purity
98%
Supply Ability
1Ton
Release date
2022-10-12
Wuhan Quanjinci New Material Co.,Ltd.
Product
Lanreotide 108736-35-2
Price
US $60.00/g
Min. Order
1g
Purity
0.99
Supply Ability
100000kgs
Release date
2023-11-02

108736-35-2, LanreotideRelated Search:

Cetrorelix acetate Lanreotide Acetate Calcitonin salmon Elcatonin Leuprorelin acetate Gonadorelin acetate Ipamorelin Liraglutide Cetrorelix acetate Glucagon Degarelix Exenatide acetate Goserelin Lixisenatide Lanreotide DOTA-BIM-23014:DOTA-Lanreotide,DOTA-Lanreotide LANREOTIDE ACETATE yttrium 90-DOTA-lanreotide

  • LANREOTIDE
  • AUTOGEL
  • BETA-(2-NAPHTHYL)-D-ALA-CYS-TYR-D-TRP-LYS-VAL-CYS-THR AMIDE
  • BIM-23014
  • ANGIOPEPTIN
  • H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-NH2
  • H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-NH2, (DISULFIDE BOND)
  • IPSTYL
  • DC-13-116
  • (D-2-NAL5,CYS6,11,TYR7,D-TRP8,VAL10)-SOMATOSTATIN (5-12) AMIDE
  • B-NAPHTHYL-D-ALA-CYS-TYR-D-TRP*LYS-VAL-C YS-THR AMID
  • bim-23014c
  • β-(2-naphthyl)-d-ala-cys-tyr-d-trp-lys-val-cys-thr amide [disulfide bridge: 2-7]
  • L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-Tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7) disulfide, TFA salt
  • 3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2-7)-disulfide
  • 3-(2-Naphtyl)-D-Ala-L-Cys(1)-L-Tyr-D-Trp-L-Lys-L-Val-L-Cys(1)-L-Thr-NH2
  • D-βNal-L-Cys(1)-L-Tyr-D-Trp-L-Lys-L-Val-L-Cys(1)-L-Thr-NH2
  • Somatuline
  • DC-13-116, Angiopeptin, (D-2-Nal5,Cys6'11,Tyr7,D-Trp8,Val10)-SoMatostatin (5-12) aMide, BIM-23014, (D-2-Nal5,Cys6·11,Tyr7,D-Trp8,Val10)-SoMatostatin (5-12) aMide
  • Lanreotide, Angiopeptin
  • B-naphthyl-D-ala-cys-tyr-D-trp*lys-val-cys-thr am
  • LaroMustine
  • Lanreotide?Acetate impurity
  • Lanreotide USP/EP/BP
  • (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
  • Lanreotide D8Q: What is Lanreotide D8 Q: What is the CAS Number of Lanreotide D8 Q: What is the storage condition of Lanreotide D8 Q: What are the applications of Lanreotide D8
  • TIANFUCHEM---108736-35-2---Lanreotide
  • Lanreotide Acetate(net)
  • L-Threoninamide,3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-,cyclic (2&reg
  • (4R,7S,10S,13R,16S,19R)-13-((1H-Indol-3-yl)methyl)-19-((R)-2-amino-3-(naphthalen-2-yl)propanamido)-N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-10-(4-aminobutyl)-16-(4-hydroxybenzyl)-7-isopropyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide
  • T4 40mcg, 100 tablets
  • *Tributyl Acetylcitrate Impurity 7
  • Lanreotide Angiopeptin acetate
  • Lanreotide Ditrifluoroacetate
  • Lanreotide, Somatostatin receptor analog
  • D8-Lanreotide
  • 108736-35-2
  • Peptides
  • Somatostatins
  • Amino Acids and Peptides
  • Biochemicals and Reagents
  • BioChemical
  • hormones